Xeris Biopharma Holdings Inc
NASDAQ:XERS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xeris Biopharma Holdings Inc
NASDAQ:XERS
|
US |
|
M
|
Magis SpA
MIL:MGS
|
IT |
|
Koppers Holdings Inc
NYSE:KOP
|
US |
|
Goldman Sachs Group Inc
NYSE:GS
|
US |
Wall St Price Targets
XERS Price Targets Summary
Xeris Biopharma Holdings Inc
According to Wall Street analysts, the average 1-year price target for XERS is 11.51 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is XERS's stock price target?
Price Target
11.51
USD
According to Wall Street analysts, the average 1-year price target for XERS is 11.51 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.
What is the Revenue forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
24%
Over the last 8 years, the compound annual growth rate for Revenue has been 92%. The projected CAGR for the next 3 years is 24%.
What is the Gross Profit forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
25%
Over the last 8 years, the compound annual growth rate for Gross Profit has been 88%. The projected CAGR for the next 3 years is 25%.
What is the Operating Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
80%
The compound annual growth rate for Operating Income over the next 3 years is 80%.
What is the Pre-Tax Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
517%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 517%.
What is the Net Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
488%
The compound annual growth rate for Net Income over the next 3 years is 488%.
